Recent clinical trials have indicated that activating the cGMP-protein kinase G (PKG) signaling pathway can yield positive outcomes in heart failure treatment, although results have been mixed for ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

The new findings bring us one step closer to therapeutically targeting this pathway to develop an improved treatment for the prevention of heart failure, Dr. Hazen says.

CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...

Gut microbial pathway identified as target for improved heart disease treatment Study shows beta-2 adrenergic receptors can be regulated from a new site which allows healthy signals through ...